ilmn result call focus growth concept
clinical/consum elast updat
limit call ship impli order remain
qr pt
underweight thesi pressur share
enthusiasm high among investor custom consid guidanc
includ fx benefit array sequenc busi remain low
doubl digit grower think beg question sustain
multipl tough comp ahead instrument ramp begin
normal messag concentr critic theme
specif model growth profil post guidanc present
earli januari note revenu mix shift
clinical/transl includ oncolog reimburs improv
clinic nipt consum array market inflect price lower
expect set placement persist multipl year
point disagr thesi ilmn view agre
clinic consum like remain strong though somewhat less bullish
shipment medium term pt goe base yield
primari concern valuat current market environ
multipl like remain higher
new news call headlin result guidanc came earli
includ shipment expect vs impli least
order per quarter sequenti flat unit ship though normal
season like near expect array growth remain rang
like stronger post holiday promot order guidanc call
qr/qr declin includ big array quarter post holiday
line stronger consensu tax fx tailwind
estim fx drive revenu growth growth
guidanc expect instrument revenu offset
declin hiseq/x sale consum saw benefit earli user
uptak expect clariti sustain pull
rais estim pt shipment servic strength
consum q/q stock order like budget flush
expect go-forward rang pull-through averag
though like take util reach steadi state
iseq interest expans down-market like financi
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
materi intend disclos placement
reason updat model reflect order
slower decommiss hiseq hsx faster servic growth
behind sustain dtc custom momentum result rais
revenu estim ep higher mix
shift toward arrays/servic drive margin headwind see chang
exhibit rais pt base yield estim
growth unlik satisfi multipl
growth unlik satisfi
multipl
cancer prenat becom standard care next
month market penetr follow adopt curv like new drug
new diagnost test regulatori approv guidelin inclus drive
clinician adopt new approach cancer prenat care guidelin
revis support cancer prenat test uptak
reimburs clinic applic improv test standard
guidelin revis support medicar code refin research
market growth improv success penetr smaller lab
novaseq launch support near-term double-digit top-line growth
consum slow inflect oncolog remain event
uptak clinic applic remain concentr academ
commun hospit refin eas use new
softwar sampl prepar system on-going regulatori approv
guidelin inclus anticip emerg year research
market growth remain weak competit emerg medium
growth slow ahead broader clinic adopt placement novaseq
hiseq system slower expect demand prove
limit outsid major genom center uptak clinic applic
remain concentr academ commun center
refin eas use new softwar sampl prepar system
on-going reimburs clinic applic remain limit
privat pay group despit progress medicar code rate regulatori
approv guidelin inclus cancer prenat applic
uncertain call long-term outcom data becom pronounc
research market remain roughli flat govern budget pressur
interest competit platform grow threaten domin
domin player next-
gener sequenc
expect broader applic
diagnost aid cancer prenat
applic longer term expect
traction measur ahead updat
clinic guidelin widespread
reimburs emerg
market like remain subdu due
physician group support clinic
guidelin evolut broader adopt
clinic set look public
expert consortia clinic trial
fda insur support includ
regulatori approv standard test
posit reimburs polici
expand interest research tailor
innov sampl prepar
softwar support adopt user
smaller clinic hospit
clinic trial readout
support broader human sequenc
limit diagnost oncolog
increas trend sourc sequenc
lab limit instrument demand
risk achiev price
clinic trial ahead timelin
updat clinic guidelin support
broad use oncolog applic
reacceler research channel
meaning competit emerg
medium term
guidanc
guidanc
lower
exhibit chang forecast
extend ra panel vectibix
phase analysi servic whole-genom
compani data morgan stanley research
strive trial women
ccga expand patient
philip data health system
bgi buy pacbio sequel system long read
us gr launch gr row
launch genestudio sequenc new assay
valuat risk
exhibit valuat ev/sal elev ile rel
exhibit valuat price-to-earnings ile rel
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
price target base yield estim view base
uptak clinic applic remain concentr academ
commun hospit refin eas use new softwar
sampl prepar system on-going regulatori approv guidelin
inclus anticip emerg research market growth remain
limit competit emerg medium term
valu driver includ physician group support clinic guidelin evolut
broader adopt system includ public expert consortia
clinic trial group fda insur support includ regulatori approv
standard test posit reimburs polici expand interest research
support tailor genom guid therapi innov sampl
prepar softwar support adopt user smaller clinic hospit
risk price target includ clinic trial guidelin timelin hospit
govern budget constraint new competit
